Spruce Biosciences (SPRB) Expected to Post Quarterly Earnings on Thursday

Spruce Biosciences (NASDAQ:SPRB) is expected to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($5.79) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Spruce Biosciences (NASDAQ:SPRB) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($8.94) earnings per share for the quarter, missing the consensus estimate of ($7.93) by ($1.01). On average, analysts expect Spruce Biosciences to post $-22 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Spruce Biosciences Stock Performance

Shares of SPRB opened at $46.61 on Thursday. The stock has a market capitalization of $128.18 million, a P/E ratio of -1.27 and a beta of 3.23. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.67 and a current ratio of 4.67. Spruce Biosciences has a 1 year low of $7.00 and a 1 year high of $240.00. The company’s fifty day moving average is $48.73 and its two-hundred day moving average is $58.34.

Institutional Trading of Spruce Biosciences

A number of institutional investors have recently added to or reduced their stakes in SPRB. Ikarian Capital LLC boosted its holdings in Spruce Biosciences by 810.3% during the fourth quarter. Ikarian Capital LLC now owns 121,356 shares of the company’s stock worth $10,571,000 after buying an additional 108,024 shares in the last quarter. Squadron Capital Management LLC purchased a new position in Spruce Biosciences in the fourth quarter valued at about $6,098,000. Wellington Management Group LLP acquired a new stake in shares of Spruce Biosciences during the 4th quarter valued at approximately $5,135,000. ADAR1 Capital Management LLC acquired a new stake in shares of Spruce Biosciences during the 4th quarter valued at approximately $5,052,000. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of Spruce Biosciences during the 4th quarter worth approximately $4,501,000. Hedge funds and other institutional investors own 91.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. B. Riley Financial began coverage on shares of Spruce Biosciences in a research note on Monday, July 13th. They set a “buy” rating and a $160.00 price target on the stock. Guggenheim began coverage on Spruce Biosciences in a report on Tuesday, June 16th. They issued a “buy” rating and a $123.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Spruce Biosciences in a research report on Friday, June 5th. JonesTrading started coverage on Spruce Biosciences in a report on Tuesday, June 9th. They issued a “buy” rating and a $135.00 price target for the company. Finally, Craig Hallum assumed coverage on Spruce Biosciences in a research note on Monday, April 27th. They issued a “buy” rating and a $140.00 price target on the stock. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Spruce Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $162.62.

About Spruce Biosciences

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.